Early Occurrence of RASSF1A Hypermethylation and Its Mutual Exclusion with BRAF Mutation in Thyroid Tumorigenesis

Cancer Research

Volumn 64, Issue 5, 2004, Pages 1664-1668

  Xing, Mingzhao ^a   Cohen, Yoram ^a   Mambo, Elizabeth ^a   Tallini, Giovanni ^b,c   Udelsman, Robert ^b   Ladenson, Paul W ^a   Sidransky, David ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BELLARIA HOSPITAL   (Italy)

^d Div of Hd and Neck Cancer Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; B RAF KINASE; BRAF PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN RET; PROTEIN TYROSINE KINASE; RAF PROTEIN; RASSF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ALLELE; ARTICLE; BRAF GENE; CARCINOGENESIS; EPIGENETICS; EPITHELIUM CELL; GENE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; METHYLATION; ONCOGENE RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THYROID ADENOMA; THYROID FOLLICLE CELL; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID TUMOR; TUMOR SUPPRESSOR GENE; DNA METHYLATION; GENE REARRANGEMENT; GENETICS; MUTATION; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA METHYLATION; GENE REARRANGEMENT; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 1642272931     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3242     Document Type: Article

References (35)

1. Meier, C. A. Thyroid nodules: pathogenesis, diagnosis and treatment. Baillieres Best Pract. Res. Clin. Endocrinol. Metab., 14: 559-575, 2000.
2. Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., and Fagin, J. A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res., 63: 1454-1457, 2003.
3. Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., and Sidransky, D. BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst., 95: 625-627, 2003.
4. Soares, P., Trovisco, V., Rocha, A. S., Lima, J., Castro, P., Preto, A., Maximo, V., Botelho, T., Seruca, R., and Sobrinho-Simoes, M. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene, 22: 4578-4580, 2003.
5. Xu, X., Quiros, R. M., Gattuso, P., Ain, K. B., and Prinz, R. A. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res., 63: 4561-4567, 2003.
6. Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T. I., Ohtsuru, A., Saenko, V. A., Kanematsu, T., and Yamashita, S. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J. Clin. Endocrinol. Metab., 88: 4393-4397, 2003.
7. Fukushima, T., Suzuki, S., Mashiko, M., Ohtake, T., Endo, Y., Takebayashi, Y., Sekikawa, K., Hagiwara, K., and Takenoshita, S. BRAF mutations in papillary carcinomas of the thyroid. Oncogene, 22: 6455-6457, 2003.
8. Moretti, F., Nanni, S., and Pontecorvi, A. Molecular pathogenesis of thyroid nodules and cancer. Baillieres Best Pract. Res. Clin. Endocrinol. Metab., 14: 517-539, 2000.
9. Kroll, T. G., Sarraf, P., Pecciarini, L., Chen, C. J., Mueller, E., Spiegelman, B. M., and Fletcher, J. A. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science (Wash. DC), 289: 1357-1360, 2000.
10. Schneider, A. B., Shore-Freedman, E., Ryo, U. Y., Bekerman, C., Favus, M., and Pinsky, S. Radiation-induced tumors of the head and neck following childhood irradiation. Prospective studies. Medicine (Baltimore), 64: 1-15, 1985.
11. Namba, H., Matsuo, K., and Fagin, J. A. Clonal composition of benign and malignant human thyroid tumors. J. Clin. Investig., 86: 120-125, 1990.
12. Apel, R. L., Ezzat, S., Bapat, B. V., Pan, N., LiVolsi, V. A., and Asa. S. L. Clonality of thyroid nodules in sporadic goiter. Diagn. Mol. Pathol., 4: 113-121, 1995.
13. Krohn, K., and Paschke, R. Somatic mutations in thyroid nodular disease. Mol. Genet. Metab., 75: 202-208, 2002.
14. Paschke, R. Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism. Exp. Clin. Endocrinol. Diabetes, 104(Suppl. 4): 129-132, 1996.
15. Mazzaferri, E. L. Management of a solitary thyroid nodule. N. Engl. J. Med., 328: 553-559, 1993.
16. Garcia-Rostan, G., Zhao, H., Camp, R. L., Pollan, M., Herrero, A., Pardo, J., Wu, R., Carcangiu, M. L., Costa, J., and Tallini, G. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J. Clin. Oncol., 21: 3226-3235, 2003.
17. Baylin, S. B. Mechanisms underlying epigenetically mediated gene silencing in cancer. Semin. Cancer Biol., 12: 331-337, 2002.
18. Dammann, R., Li, C., Yoon, J. H., Chin, P. L., Bates, S., and Pfeifer, G. P. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet., 25: 315-319, 2000.
19. Pfeifer, G. P., Yoon, J. H., Liu, L., Tommasi, S., Wilczynski, S. P., and Dammann, R. Methylation of the RASSF1A gene in human cancers. Biol. Chem., 383: 907-914, 2002.
20. Schagdarsurengin, U., Gimm, O., Hoang-Vu, C., Dralle, H., Pfeifer, G. P., and Dammann, R. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res., 62: 3698-3701, 2002.
21. Xing, M., Usadel, H., Cohen, Y., Tokumaru, Y., Guo, Z., Westra, W. B., Tong, B. C., Tallini, G., Udelsman, R., Califano, J. A., Ladenson, P. W., and Sidransky, D. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res., 63: 2316-2321, 2003.
22. Jeronimo, C., Usadel, H., Henrique, R., Oliveira, J., Lopes, C., Nelson, W. G., and Sidransky, D. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl. Cancer Inst., 93: 1747-1752, 2001.
23. Lehmann, U., Langer, F., Feist, H., Glockner, S., Hasemeier, B., and Kreipe, H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am. J. Pathol., 160: 605-612, 2002.
24. Monney, L., Sabatos, C. A., Gaglia, J. L., Ryu, A., Waldner, H., Chernova, T., Manning, S., Greenfield, E. A., Coyle, A. J., Sobel, R. A., Freeman, G. J., and Kuchroo, V. K. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature (Lond.), 415: 536-541, 2002.
25. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., and Futreal, P. A. Mutations of the BRAF gene in human cancer. Nature (Lond.), 417: 949-954, 2002.
26. Fagin, J. A. Tumor suppressor genes in human thyroid neoplasms: p53 mutations are associated undifferentiated thyroid cancers. J. Endocrinol. Investig., 18: 140-142, 1995.
27. Herrmann, M. A., Hay, I. D., Bartelt, D. H., Jr., Ritland, S. R., Dahl, R. J., Grant, C. S., and Jenkins, R. B. Cytogenetic and molecular genetic studies of follicular and papillary thyroid cancers. J. Clin. Investig., 88: 1596-1604, 1991.
28. van Engeland, M., Roemen, G. M., Brink, M., Pachen, M. M., Weijenberg, M. P., de Bruine, A. P., Arends, J. W., van den Brandt, P. A., de Goeij, A. F., and Herman, J. G. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene, 21: 3792-3795, 2002.
29. Dammann, R., Schagdarsurengin, U., Liu, L., Otto, N., Gimm, O., Dralle, H., Boehm, B. O., Pfeifer, G. P., and Hoang-Vu, C. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene, 22: 3806-3812, 2003.
30. Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (Lond.), 418: 934, 2002.
31. Chan, T. L., Zhao, W., Leung, S. Y., and Yuen, S. T. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res., 63: 4878-4881, 2003.
32. Gorden, A., Osman, I., Gai, W., He, D., Huang, W., Davidson, A., Houghton. A. N., Busam, K., and Polsky, D. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res., 63: 3955-3957, 2003.
33. Singer, G., Oldt, R., 3rd, Cohen, Y., Wang, B. G., Sidransky, D., Kurman, R. J., and Shih Ie, M. Mutations in BRAF and KRAS characterize the development of lowg-rade ovarian serous carcinoma. J. Natl. Cancer Inst., 95: 484-486, 2003.
34. Nikiforov, Y. E. RET/PTC rearrangement in thyroid tumors. Endocr. Pathol., 13: 3-16, 2002.
35. Suarez, H. G. Genetic alterations in human epithelial thyroid tumours. Clin. Endocrinol. (Oxf), 48: 531-546, 1998.